Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
For those new to NSCI, have a look at the portfolio listed on the website. It will give you a good feel for the potential of this company.
https://netscientific.net/portfolio/emv-capital/
https://www.investorschronicle.co.uk/ideas/2023/02/09/bargain-shares-2023/
NSCI makes the list!
NSCI only have a 1% holding but still looks like a great product for an important illness.
https://www.verywellhealth.com/new-screening-test-for-sepsis-7097947
https://www.youtube.com/watch?v=sRP1HeuaNL0
Found the link, go to 44 mins.
With Covid coming back in to the headlights it would be good to know what is happening since this update in May.
ProAxsis has completed the development and validation of the AstraZeneca COVID-19 antibody test with "impressive performance evaluation results."
In June 2021 ProAxsis entered into an exclusive licensing agreement with the global biopharmaceutical company AstraZeneca, under which ProAxsis took responsibility for completing the development, validation and global commercialisation of a SARS-CoV-2 (the virus associated with COVID-19) serology ELISA (enzyme-linked immunosorbent assay).
Overall survival = OS
Median OS is 21 months in 29 checkpoint inhibitor refractory patients who received the triple combination. The reported historical median OS in patients with CPI refractory disease is 3-4 months.
In CPI naïve subjects, 75% remain alive at a median follow-up of 27 months. As a result, median OS has not yet been reached. Historically median OS for similar patients with platinum experienced CPI naïve disease is 7-11 months.
Sagetech medical also has a new website. Looks like they are ready to go commercial.
https://www.sagetechmedical.com/products-services/
Our portfolio company FOx Biosystems has been awarded €2.5 million European Innovation Council and SMEs Executive Agency (EISMEA) grant to accelerate the market introduction of unique Extracellular Vesicle (EV) analysis and isolation application.
Thomas van Elzakker, CEO of FOx Biosystems comments: “This grant is a clear validation of the urgent need for the benefits we offer to the fast-growing EV research market. It recognizes the unique potential value of our technology to obtain high quality and unbiased research data in this field, removing the current bottlenecks scientists are struggling with.''
https://www.linkedin.com/posts/sagetech-medical_sidsolutions-siddock-circulareconomy-activity-7006920583959465984-pMlc?utm_source=share&utm_medium=member_ios
Seems like a lot is going on at Sagetech.
https://www.linkedin.com/posts/carlos-jaureguizar_in-our-second-year-of-eco-disruptive-im-activity-7006679425362649089-uecq?utm_source=share&utm_medium=member_ios
https://www.linkedin.com/posts/emvcapital_constructiontech-eisinvestment-climatechangeinvestment-activity-7006664588930822144-esc-?utm_source=share&utm_medium=member_ios
Good interview by Frank (CEO PDSB).
https://tradersnewssource.com/interview-pdsb/